metaEvidence - overview


			deaths (OS)
metastatic, hormone-sensitive prostate cancer metastatic, hormone-sensitive prostate cancer
versus androgen deprivation therapy (ADT)
	abiraterone plus ADT vs. androgen deprivation therapy (ADT)	2	0.63 [0.54; 0.72], 2 RCTs, I2=0% conclusive unassessable degree of certainty
	apalutamide plus ADT vs. androgen deprivation therapy (ADT)	1	0.67 [0.51; 0.89], 1 RCT, I2=0% conclusive unassessable degree of certainty
	docetaxel plus ADT vs. androgen deprivation therapy (ADT)	4	0.76 [0.64; 0.90], 4 RCTs, I2=54% conclusive unassessable degree of certainty
	enzalutamide plus ADT vs. androgen deprivation therapy (ADT)	2	0.66 [0.56; 0.78], 2 RCTs, I2=0% unassessable degree of certainty
versus docetaxel plus ADT
	abiraterone plus docetaxel plus ADT vs. docetaxel plus ADT	1	0.75 [0.59; 0.95], 1 RCT, I2=0% conclusive unassessable degree of certainty
	darolutamide plus doxetaxel plus ADT vs. docetaxel plus ADT	1	0.68 [0.57; 0.81], 1 RCT, I2=0% conclusive unassessable degree of certainty